8-K: Stoke Therapeutics Q2: Clinical Progress & Strong Cash

Stoke Therapeutics reports strong Q2 2025 financial results, initiates Phase 3 for zorevunersen in Dravet syndrome, and advances STK-002 for ADOA.

Summary

• Stoke Therapeutics reported a net loss of $23.5 million, or $0.40 per share, for the second quarter ended June 30, 2025, compared to a net loss of $25.7 million, or $0.46 per share, for the same period in 2024.
• For the six months ended June 30, 2025, the company reported a net income of $89.4 million, or $1.50 per diluted share, a significant improvement from a net loss of $52.1 million, or $1.02 per share, for the same period in 2024.
• Revenue for the second quarter of 2025 was $13.8 million, up from $4.8 million in Q2 2024, primarily due to collaboration agreements.
• Year-to-date revenue for 2025 reached $172.4 million, compared to $9.0 million for the same period in 2024.
• As of June 30, 2025, the company held $355.0 million in cash, cash equivalents, and marketable securities, which is anticipated to fund operations to mid-2028 and into launch readiness.
• The first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome.
• New 3-year open-label extension (OLE) data for zorevunersen in Dravet syndrome patients show substantial and durable reductions in convulsive seizure frequency, along with continued improvements in cognition and behavior, and a generally well-tolerated safety profile.
• The Phase 1 study (OSPREY) of STK-002 has been initiated in patients with Autosomal Dominant Optic Atrophy (ADOA), marking the advancement of a second clinical program.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical progress with the initiation of a Phase 3 study and positive long-term OLE data for its lead candidate, zorevunersen. It also expands its pipeline with a new Phase 1 study for STK-002. Financially, the company achieved a significant year-to-date net income and has a robust cash position extending its runway for several years. While expenses increased, this is attributed to clinical development and launch readiness, indicating strategic investment. The only minor negative is the high incidence of CSF protein elevation, though mostly asymptomatic.

Positives

• Achieved a net income of $89.4 million for the six months ended June 30, 2025, a significant turnaround from a net loss of $52.1 million in the prior year period.
• Reported substantial revenue growth, with Q2 2025 revenue at $13.8 million (vs. $4.8 million in Q2 2024) and YTD 2025 revenue at $172.4 million (vs. $9.0 million in YTD 2024), driven by collaboration agreements.
• Maintained a strong cash position of $355.0 million as of June 30, 2025, providing an anticipated cash runway to mid-2028 and into launch readiness.
• Initiated the global Phase 3 EMPEROR study for zorevunersen in Dravet syndrome, a critical step towards potential regulatory approval.
• Presented positive 3-year open-label extension (OLE) data for zorevunersen, demonstrating durable reductions in seizures and continued improvements in cognition and behavior, supporting its disease-modifying potential.
• Expanded the clinical pipeline by initiating a Phase 1 study (OSPREY) of STK-002 for Autosomal Dominant Optic Atrophy (ADOA), addressing an unmet medical need.
• Zorevunersen has received Breakthrough Therapy Designation from the FDA, potentially expediting its development and review process.

Negatives

• Reported a net loss of $23.5 million for the second quarter of 2025, despite the overall year-to-date net income.
• Research and development expenses increased to $25.9 million in Q2 2025 (from $21.1 million in Q2 2024) and $58.5 million YTD 2025 (from $43.5 million YTD 2024), reflecting higher costs associated with clinical development.
• General and administrative expenses also increased to $15.3 million in Q2 2025 (from $13.0 million in Q2 2024) and $29.9 million YTD 2025 (from $23.3 million YTD 2024), partly due to launch readiness expenses.
• Cerebrospinal fluid (CSF) protein elevation occurred in 86% of patients in OLE studies, classified as a treatment-emergent adverse event (TEAE) in 45%, although no clinical manifestations were observed, and one patient discontinued treatment due to this.

Risks

• The company's ability to advance, obtain regulatory approval, and ultimately commercialize its product candidates, including zorevunersen and STK-002, is uncertain.
• If Biogen were to breach or terminate the collaboration agreement, the company may not obtain the anticipated financial or other benefits.
• There is a possibility that the company and Biogen may not be successful in their development of zorevunersen, and even if successful, they may be unable to successfully commercialize it.
• Positive results in a clinical trial may not be replicated in subsequent trials, and successes in early-stage clinical trials may not be predictive of results in later-stage trials.
• The company's ability to protect its intellectual property is crucial for its long-term success.
• The company's ability to fund development activities and achieve development goals through mid-2028 is subject to various factors.
• Global business, political, and macroeconomic conditions, including inflation, interest rate volatility, cybersecurity events, uncertainty with respect to the federal budget, instability in the global banking system, and volatile market conditions, could adversely affect operations.
• Global events, including public health crises and ongoing geopolitical conflicts such as those in Ukraine and the Middle East, pose risks.
• Regulatory authorities may interpret or weigh the importance of data differently, request additional information, or change their guidance or requirements before or after approval.
• Receiving Breakthrough Therapy Designation does not guarantee faster development, regulatory review, or marketing approval for zorevunersen.

Future Outlook

The company plans to present additional data from the zorevunersen clinical development program at upcoming medical congresses in 2025. Lead optimization is underway to identify a clinical candidate for SYNGAP-1 in 2026. Data from the EMPEROR Phase 3 study are anticipated in the second half of 2027. The current cash position is expected to fund operations to mid-2028 and into launch readiness.

Management Comments

• "This quarter was defined by strong execution that is driving momentum across our business." Ian F. Smith, Interim Chief Executive Officer and Director.
• "Our Phase 1/2 and open-label extension studies have provided a strong foundational understanding of zorevunersen and support the EMPEROR Phase 3 registrational study design." Ian F. Smith.
• "We continue to generate long-term data that are helping us appreciate the disease modifying potential of zorevunersen." Ian F. Smith.
• "Beyond Dravet, we have initiated clinical development in a second disease area, advancing STK-002 into a Phase 1 study in patients with Autosomal Dominant Optic Atrophy." Ian F. Smith.
• "Our pre-clinical data support the potential for STK-002 to restore naturally-occurring protein expression to maintain or improve vision in these patients." Ian F. Smith.
• "We look forward to continuing to expand our approach into new disease areas where we believe we can deliver first-in-class, disease modifying medicines for severe genetic diseases." Ian F. Smith.

Industry Context

Stoke Therapeutics operates in the specialized field of rare genetic diseases, focusing on conditions caused by haploinsufficiency, where insufficient protein levels lead to disease. Dravet syndrome, a severe neurodevelopmental and epileptic encephalopathy affecting up to 38,000 people in key markets, currently lacks disease-modifying treatments, with existing therapies primarily managing seizures. Zorevunersen aims to address this unmet need by increasing NaV1.1 protein production. Similarly, Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder affecting approximately one in 30,000 people globally, has no approved treatments. STK-002 is positioned to be a first-in-class therapy by restoring OPA1 protein expression. This strategic focus on orphan diseases with high unmet needs positions Stoke to potentially capture significant market share if its therapies prove successful.

Comparison to Industry Standards

• Zorevunersen is positioned as the first potential disease-modifying medicine for Dravet syndrome, differentiating it from current standard-of-care anti-seizure medications (e.g., Bromide, Clobazam, Fenfluramine, Stiripentol, Valproate, Cannabinoid, Diazepam, Levetiracetam, Topiramate, Zonisamide) which primarily aim to reduce seizures but do not address cognitive and behavioral challenges.
• The company highlights that there are currently no approved treatments for Autosomal Dominant Optic Atrophy (ADOA), positioning STK-002 as a potential first-in-class disease-modifying therapy for this condition.
• The use of the Vineland-3 Adaptive Behavior Scales to evaluate non-seizure outcomes (cognition and behavior) in Dravet syndrome is a commonly accepted and standardized assessment tool in the industry for neurodevelopmental disorders.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical progress, expanded pipeline, improved financial performance (YTD net income), and extended cash runway, potentially increasing shareholder value.
• Patients (Dravet syndrome): Positive impact due to advancement of zorevunersen into Phase 3 and promising long-term OLE data, offering hope for a disease-modifying treatment.
• Patients (ADOA): Positive impact due to the initiation of a Phase 1 study for STK-002, addressing an unmet medical need for a progressive vision disorder.
• Employees: Potential positive impact due to increased personnel and launch readiness expenses, suggesting growth and stability.
• Collaborators (Biogen, Acadia Pharmaceuticals): Continued collaboration and revenue generation indicate a healthy partnership.

Next Steps

• Present additional data from the zorevunersen clinical development program at upcoming medical congresses in 2025.
• Lead optimization to identify a clinical candidate for SYNGAP-1 in 2026.
• Anticipated data from the EMPEROR Phase 3 study in 2H 2027.
• Continue the Phase 1 OSPREY study of STK-002 in ADOA patients.

Key Dates

Recommendation

The company has achieved significant clinical milestones, including the initiation of a pivotal Phase 3 study for its lead candidate, zorevunersen, which has shown compelling long-term disease-modifying potential in OLE studies. The expansion into a second clinical program (STK-002 for ADOA) further diversifies its pipeline. Financially, the company has demonstrated a remarkable turnaround, reporting a substantial year-to-date net income and maintaining a strong cash position that provides a runway well into 2028. These factors, combined with addressing high unmet medical needs in rare genetic diseases, position Stoke Therapeutics for significant future growth and value creation, making it a compelling investment.

Keywords

Biotechnology, Dravet syndrome, zorevunersen, STK-002, Autosomal Dominant Optic Atrophy, ADOA, SCN1A, OPA1, RNA medicine, antisense oligonucleotide, ASO, clinical trials, Phase 3, rare disease, neurodevelopmental, genetic disease, TANGO, financial results, Q2 2025